Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

. At January 31, 2008, the company had $20,063,000 in cash and cash equivalents compared to $16,044,000 at fiscal year end April 30, 2007.

"The past quarter was highlighted by a major milestone in our oncology program, as we dosed the first patients in a Phase II trial evaluating bavituximab in combination with chemotherapy in patients with breast cancer," said Steven W. King, president and CEO of Peregrine. "We also received regulatory approval to initiate two additional bavituximab Phase II cancer trials -- a second breast cancer study and a trial in patients with non-small cell lung cancer, a leading cause of cancer deaths worldwide. Planning for these trials is well underway and we anticipate initiating both studies next month. We also made progress in our Cotara clinical program in patients with glioblastoma multiforme (GBM), today announcing promising data from the ongoing dosimetry and Phase II trials showing that several patients are already surviving longer than the expected six-month median survival time for this patient population, with the longest surviving patient now at 15 months post-treatment. Patients who are continuing in the trials are being monitored for safety and overall survival, and we look forward to providing further updates on these trials going forward. We have also recently expanded the number of clinical sites in the Phase Il study to eight and also added a distinguished brain cancer center and experienced Cotara clinical study site -- the Barrow Neurological Institute -- to our dosimetry study in the U.S."

Mr. King added, "Our initiative to raise awareness for the bavituximab and Cotara programs in the scientific and medical communities scored gains, including an oral presentation covering the clinical experience to date in the bavituximab Phase I cancer program at Angio 2008, an oral presentation of clinical data from our Phase I bavituximab trial in hepatitis C patients at the prestigious 2007 Liver Meeting(R), a recent
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... A new research platform uses a ... tiny structures undergoing stress and heating, an ... designs for microelectronics and batteries., This new ... about how heating and the surface stress ... Researchers have discussed the merits of surface-stress ...
(Date:8/28/2014)... The ability for organizations to attract ... allow individuals to perform at the highest of levels, ... looking to compete in this post–recession era. The ... as the sector increasingly focuses on the importance of ... have real results on the organization's development and the ...
(Date:8/28/2014)... 2014 Sterlitech is proud to announce ... its stable of products . These additional ... and include membrane filters with surface charges. ... demand for our membrane process testing equipment, and correspondingly, ... sheet membranes,” explains Sterlitech President Mark Spatz. “The ...
(Date:8/28/2014)... Scientists, researchers, and technologists will converge ... Damage 2014 symposium. Marking its 46th year, the ... run 14-17 September. The event is sponsored by ... , The premier conference for basic and applied issues ... materials will engage researchers and engineers from numerous industries ...
Breaking Biology Technology:New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... 7 Nektar,Therapeutics (Nasdaq: NKTR ) President and ... upcoming Natixis Bleichroeder Second Annual Hidden Gems,Conference in New ... at 2:30 p.m. ET., The presentation will be ... Relations, Events Calendar section of the Nektar website:, http://www.nektar.com ...
... Customer the Broad Institute of MIT and Harvard, Among ... ... 7 Isilon(R) Systems (Nasdaq:,ISLN), the leader in clustered storage, ... the growing data storage,challenges facing life science research organizations as ...
... Oct. 6 NEXCORE Technology, Inc., a,world-class original ... agreement with GI Supply of Camp Hill, Pa, ... Polar Wand is a portable,device that uses endoscopic ... gastrointestinal tract in patients resistant to conventional,endoscopic therapy., ...
Cached Biology Technology:Isilon CTO Addresses Life Science Data Storage Challenges at Harvard Medical School's BioMedical HPC Leadership Summit 2Isilon CTO Addresses Life Science Data Storage Challenges at Harvard Medical School's BioMedical HPC Leadership Summit 3NEXCORE Technology Selected to Manufacture New Endoscopic Cryotherapy Device 2
(Date:9/1/2014)... BOSTON (September 1, 2014, 10:20 AM EDT) It ... healthy low-calorie foods over unhealthy higher-calorie foods, according to ... Human Nutrition Research Center on Aging (USDA HNRCA) at ... today in the journal Nutrition & Diabetes , ... suggests that it is possible to reverse the addictive ...
(Date:9/1/2014)... animals, bats are perfectly adapted to a life without light. ... reflected echoes to measure distance to obstacles or prey. In ... delays. A study carried out by researchers at Technische Universitt ... map dynamically adapts to external factors. , Closer ... in too close to an object, the number of activated ...
(Date:8/31/2014)... blood test provides a fast and accurate tool ... study shows. The newly developed test (TAM-TB assay) ... active tuberculosis in children. The test features excellent ... combination with speed of a blood test. The ... diagnosis of tuberculosis in children, particularly in tuberculosis-endemic ...
Breaking Biology News(10 mins):Training your brain to prefer healthy foods 2Zooming in for a safe flight 2New tuberculosis blood test in children is reliable and highly specific 2
... , , , , ... , AUDIO: Learn ... , Click here for more information. ... , , , , , ...
... have begun to categorize breast cancers into four main ... cells. Which category a cancer falls into generally determines ... cancers in one of the four groups called ... particularly tricky to treat because they usually don,t respond ...
... host the U.S. book release of Women Scientists in ... of Academies of Science (IANAS). This compilation of ... to inspire students, especially young women, to pursue science ... Spanish, the book includes the stories of eminent female ...
Cached Biology News:Bad decisions arise from faulty information, not faulty brain circuits 2Bad decisions arise from faulty information, not faulty brain circuits 3Bad decisions arise from faulty information, not faulty brain circuits 4UCLA researchers find nanodiamonds could improve effectiveness of breast cancer treatment 2UCLA researchers find nanodiamonds could improve effectiveness of breast cancer treatment 3
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
... The Hamamatsu C9136 FLIM system combines the space ... with the resolution of the optical microscope to ... a short, pulsed light source for excitation, the ... and the lifetime of the decay measured. ...
...
SDS-OutT Precipitation Reagent...
Biology Products: